IL1RL2
Interleukin-1 receptor-like 2
As of the edition of 20 October 2026, IL1RL2 (interleukin-1 receptor-like 2, UniProt Q9HB29) has 4 drugs tested at it and 5 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9HB29
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Skin and connective tissue; Digestive system; Infections; Inherited and neonatal; Immune system
- Registered trials of its drugs
- 47
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Spesolimab | Marketed | Phase 4 | Ends 2034 |
| Imsidolimab | Stopped | Phase 3 | none listed |
| HB0034 | Active | Phase 3 | none listed |
| REGN6490 | Stopped | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 1 |
| Undetermined | 3 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Regeneron | Route A |
The other 4 companies at IL1RL2
In the product5 companies in all; 4 are not named here, and no score is.
See the 5 companies at IL1RL2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.